Hospital, New York, NY, USA); and Severgnini, Paolo* (Università dell’Insubria – Dipartimento di Anestesia – Azienda Ospedaliera ASST Sette Laghi/Ospedale di Circolo e Fondazione Macchi Varese, Italy). This article was corrected online.


Clarification of Reporting of Conflicts of Interest: In the Original Investigation entitled “Effect of Selepressin vs Placebo on Ventilator- and Vasopressor-Free Days in Patients With Septic Shock: The SEPSIS-ACT Randomized Clinical Trial”1 published in the October 15, 2019, issue of JAMA, potential conflicts of interest were inadvertently omitted for 2 authors. Dr Graves’ disclosure should have read: “Dr Graves reported that he is an employee of Berry Consultants; Berry Consultants was compensated by Ferring Pharmaceuticals for clinical design work.” Dr Lewis’ disclosure should have read: “Dr Lewis reported that he is an employee of Berry Consultants; Berry Consultants was compensated by Ferring Pharmaceuticals for clinical design work.” This article has been corrected online.


Incorrect Word Affecting Meaning of Sentence: In the USPSTF Recommendation Statement entitled “Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement”1 published in the August 20, 2019, issue of JAMA, an incorrect word affected the meaning of a sentence. In the “Importance” subsection of the “Rationale” section, the sentence that read “Mutations in the BRCA1/2 genes increase breast cancer risk by 45% to 65% by age 70 years” should have read: “Mutations in the BRCA1/2 genes increase breast cancer risk to 45% to 65% by age 70 years.” This article has been corrected online.


Guidelines for Letters

Letters discussing a recent JAMA article should be submitted within 4 weeks of the article’s publication in print. Letters received after 4 weeks will rarely be considered. Letters should not exceed 400 words of text and 5 references and may have no more than 3 authors. Letters reporting original research should not exceed 600 words of text and 6 references and may have no more than 7 authors. They may include up to 2 tables or figures but online supplementary material is not allowed. All letters should include a word count. Letters must not duplicate other material published or submitted for publication. Letters not meeting these specifications are generally not considered. Letters being considered for publication ordinarily will be sent to the authors of the JAMA article, who will be given the opportunity to reply. Letters will be published at the discretion of the editors and are subject to abridgement and editing. Further instructions can be found at http://jamanetwork.com/journals/jama/pages/instructions-for-authors. A signed statement for authorship criteria and responsibility, financial disclosure, copyright transfer, and acknowledgment are required before publication. Letters should be submitted via the JAMA online submission and review system at https://manuscripts.jama.com. For technical assistance, please contact jama-letters@jamanetwork.org.

Section Editor: Jody W. Zylke, MD, Deputy Editor.